Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; butylated hydroxyanisole; lactose monohydrate; citric acid monohydrate; ascorbic acid; titanium dioxide; hypromellose; hyprolose; purified talc; iron oxide yellow - adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 10.85 mg (equivalent: atorvastatin, qty mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; polysorbate 80; magnesium stearate; calcium carbonate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; methyl hydroxybenzoate; dimeticone 1000; sorbitan monostearate; polysorbate 60; guar gum; bronopol - lipitor is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. lipitor is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - simvastatin -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - simvastatin -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - simvastatin -